Skin and Soft Tissue Infections - Pipeline Review, H1 2017

  • ID: 4091153
  • Drug Pipelines
  • 40 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Atox Bio Ltd
  • CorMedix Inc
  • Valevia UK Ltd
  • Wockhardt Ltd
  • MORE
Skin And Soft Tissue Infections - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Skin And Soft Tissue Infections - Pipeline Review, H1 2017, provides an overview of the Skin And Soft Tissue Infections (Dermatology) pipeline landscape.

Skin and soft tissue infections are infections involving the layers of the skin and the soft tissues beneath it. Viruses, bacteria, and fungi generally cause skin and soft tissue infections by entering the body at a spot where a cut, scrape, bite, or other wound has broken the skin. Symptoms include swelling, warmth, and redness in a distinct area of skin, abscesses, furuncles and carbuncles. Risk factors include injury to the skin, radiation therapy, accumulation of fluid (edema) due to poor circulation, heart failure, liver disease, or past surgery to remove lymph nodes, being overweight and chronic skin conditions, such as eczema.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Skin And Soft Tissue Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Skin And Soft Tissue Infections (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Skin And Soft Tissue Infections (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Skin And Soft Tissue Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1, 3 and 1 respectively.

Skin And Soft Tissue Infections (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Skin And Soft Tissue Infections (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Skin And Soft Tissue Infections (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Skin And Soft Tissue Infections (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Skin And Soft Tissue Infections (Dermatology).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Skin And Soft Tissue Infections (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Skin And Soft Tissue Infections (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Atox Bio Ltd
  • CorMedix Inc
  • Valevia UK Ltd
  • Wockhardt Ltd
  • MORE
Introduction

Skin And Soft Tissue Infections - Overview

Skin And Soft Tissue Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Skin And Soft Tissue Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Skin And Soft Tissue Infections - Companies Involved in Therapeutics Development

Atox Bio Ltd

CorMedix Inc

Takeda Pharmaceutical Company Ltd

Valevia UK Ltd

Wockhardt Ltd

Skin And Soft Tissue Infections - Drug Profiles

AB-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADEP-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alalevonadifloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ceftaroline fosamil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRMD-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-7072 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Skin and Soft Tissue Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Skin And Soft Tissue Infections - Dormant Projects

Skin And Soft Tissue Infections - Product Development Milestones

Featured News & Press Releases

Nov 03, 2016: Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections

Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections

Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)

Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority

Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections

Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial

Sep 10, 2012: Atox Bio’s AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections

Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Skin And Soft Tissue Infections, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Skin And Soft Tissue Infections - Pipeline by Atox Bio Ltd, H1

Skin And Soft Tissue Infections - Pipeline by CorMedix Inc, H1

Skin And Soft Tissue Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H1

Skin And Soft Tissue Infections - Pipeline by Valevia UK Ltd, H1

Skin And Soft Tissue Infections - Pipeline by Wockhardt Ltd, H1

Skin And Soft Tissue Infections - Dormant Projects, H1

List of Figures:

Number of Products under Development for Skin And Soft Tissue Infections, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Atox Bio Ltd
  • CorMedix Inc
  • Takeda Pharmaceutical Company Ltd
  • Valevia UK Ltd
  • Wockhardt Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll